RNS Number : 8386C
Piper Jaffray Ltd
20 November 2009
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
1. KEY INFORMATION
Name of exempt principal trader Piper Jaffray Ltd.
Company dealt in Neuropharm Group plc
Class of relevant security to which the dealings being Ord 10p
disclosed relate (Note 1)
Date of dealing 19 November 2009
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long Short
Number Number
(%)
(%)
(1) Relevant securities 67,760
0.21%
(2) Derivatives (other than
options)
(3) Options and agreements to
purchase/sell
Total 67,760
0.21%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: Long Short
Number Number
(%)
(%)
(1) Relevant securities
(2) Derivatives (other than
options)
(3) Options and agreements to
purchase/sell
Total
(c) Rights to subscribe (Note 2)
Class of relevant security: Details
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of securities Price per unit (Note 4)
Sale 55,210 18.00p
(b) Derivatives transactions (other than options)
Product name, Long/short (Note 5) Number of securities Price per unit (Note 4)
e.g. CFD (Note 6)
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of securities Exercise Type, e.g. American, Expiry Option money
e.g. call option purchasing, varying to which the option price European etc. date paid/received per
etc. relates (Note 6) unit (Note 4)
(ii) Exercising
Product name, e.g. call option Number of securities Exercise price per unit (Note 4)
(d) Other dealings (including new securities) (Note 3)
Nature of transaction (Note 7) Details Price per unit (if applicable) (Note
4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the
person disclosing and any other person relating to the voting rights of any
relevant securities under any option referred to on this form or relating to
the voting rights or future acquisition or disposal of any relevant
securities to which any derivative referred to on this form is referenced. If
none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 20 November 2009
Contact name Norman Gould
Telephone number 020 3142 8780
Name of offeree/offeror with which connected Neuropharm Group plc
Nature of connection (Note 9) Adviser and broker
Notes
The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
EMMURSKRKVRAURA
